ReviewInternational journal of nanomedicine2012
Anti-HIV-1 nanotherapeutics: promises and challenges for the future.
Review in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 133 citations in OpenAlex.
- Advancing Antibiotic-Resistant Microbe Combat: Nanocarrier-Based Systems in Combination Therapy Targeting Quorum Sensing.Pharmaceutics · 2024Review
- Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.Journal of drug delivery science and technology · 2023Review
- Review
- Review
- Formulation of Cabotegravir Loaded Gold Nanoparticles: Optimization, Characterization to In-Vitro Cytotoxicity Study.Journal of cluster science · 2023Article
- SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.Applied nanoscience · 2023Review
- Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era.National science review · 2022Review
- Characterizing Lipid-Coated Mesoporous Silica Nanoparticles as CD169-Binding Delivery System for Rilpivirine and Cabotegravir.Advanced nanobiomed research · 2022Article
- Nanodelivery of antiretroviral drugs to nervous tissues.Frontiers in pharmacology · 2022Review
- Highly active antiretroviral therapy conjugated silver nanoparticle ameliorates testicular injury in type-2 diabetic rats.Heliyon · 2021Article
- Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19.Microbial pathogenesis · 2021Review
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.Pharmacology research & perspectives · 2021Review
- Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles.Pharmaceutics · 2021Article
- Nanotechnology for virus treatment.Nano today · 2021Review
- Silver Nanoparticles Conjugate Attenuates Highly Active Antiretroviral Therapy-Induced Hippocampal Nissl Substance and Cognitive Deficits in Diabetic Rats.Journal of diabetes research · 2021Article
- Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems.Current neuropharmacology · 2021Article
- Nanotechnological strategies for systemic microbial infections treatment: A review.International journal of pharmaceutics · 2020Review
- Gold Nanoparticles for Vectorization of Nucleic Acids for Cancer Therapeutics.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
The advent of highly active antiretroviral therapy (HAART) has significantly improved the prognosis for human immunodeficiency virus (HIV)-infected patients, however the adverse side effects associated with prolonged HAART therapy use continue. Although systemic viral load can be undetectable, the virus remains sequestered in anatomically privileged sites within the body. Nanotechnology-based delivery systems are being developed to target the virus within different tissue compartments and are being evaluated for their safety and efficacy. The current review outlines the various nanomaterials that are becoming increasingly used in biomedical applications by virtue of their robustness, safety, multimodality, and multifunctionality. Nanotechnology can revolutionize the field of HIV medicine by not only improving diagnosis, but also by improving delivery of antiretrovirals to targeted regions in the body and by significantly enhancing the efficacy of the currently available antiretroviral medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.